Actinium Pharmaceuticals (ATNM) Scheduled to Post Quarterly Earnings on Sunday

Actinium Pharmaceuticals (NYSEAMERICAN:ATNMGet Free Report) will release its earnings data on Sunday, March 31st.

Actinium Pharmaceuticals Stock Down 1.4 %

Shares of NYSEAMERICAN:ATNM opened at $7.83 on Friday. The company has a market capitalization of $217.36 million, a P/E ratio of -4.08 and a beta of 0.01. Actinium Pharmaceuticals has a one year low of $4.00 and a one year high of $9.86.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. UBS Group AG lifted its stake in shares of Actinium Pharmaceuticals by 76.2% in the fourth quarter. UBS Group AG now owns 3,235 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 1,399 shares in the last quarter. Royal Bank of Canada lifted its stake in shares of Actinium Pharmaceuticals by 38.5% in the second quarter. Royal Bank of Canada now owns 6,734 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 1,871 shares in the last quarter. California State Teachers Retirement System bought a new position in shares of Actinium Pharmaceuticals during the second quarter valued at about $64,000. The Manufacturers Life Insurance Company bought a new position in shares of Actinium Pharmaceuticals during the second quarter valued at about $83,000. Finally, Deutsche Bank AG lifted its position in shares of Actinium Pharmaceuticals by 673.4% during the third quarter. Deutsche Bank AG now owns 15,235 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 13,265 shares in the last quarter. 27.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Maxim Group upped their price target on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday. StockNews.com cut shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, March 19th. Finally, B. Riley decreased their price target on shares of Actinium Pharmaceuticals from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Monday, December 11th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Actinium Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $26.92.

View Our Latest Analysis on Actinium Pharmaceuticals

Actinium Pharmaceuticals Company Profile

(Get Free Report)

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.

Recommended Stories

Earnings History for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.